Wong CKH, Man KKC, Shi M, et al. - Researchers investigated a retrospective cohort data of 17,293 people with T2DM who were free from cardiovascular disease (CVD) and on metformin-sulfonylurea (Met-SU) dual therapy and who were intensified with dipeptidyl peptidase-4 inhibitor (DPP4i), insulin, or thiazolidinedione (TZD) from 2006 to 2017 in order to contrast the risks of all-cause mortality, CVD, and severe hypoglycemia (SH) amongst individuals with T2DM on Met-SU dual therapy intensified with DPP4i, insulin, or TZD. Overall, outcomes indicated that for individuals with T2DM who were on Met-SU dual therapy, amongst three options, adding DPP4i was a preferred third-line medication with the least risks of mortality and SH and posing no raised risk for CVD events when contrasted with insulin and TZD. Moreover, intensification with insulin had the highest risk of mortality and SH events.